CytRx To Initiates Phase 2 Clinical Trial With Bafetinib
Reportedly, in the planned phase 2 trial, approximately 20 patients who have failed treatment with first-line agents will be administered daily oral doses of Bafetinib. In the study,
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
The first antibody conjugate is Nimotuzumab coupled to a radionuclide, indium-111, and a cell-nucleus delivery system developed in the laboratory of Dr. Raymond Reilly, Professor, Leslie Dan Faculty
Corvert injection (Ibutilide fumarate injection) is an antiarrhythmic drug with predominantly class III (cardiac action potential prolongation) properties according to the Vaughan Williams Classification. Each milliliter of Corvert